Filing Details
- Accession Number:
- 0001127602-11-020589
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-07-05 16:20:32
- Reporting Period:
- 2011-07-01
- Filing Date:
- 2011-07-05
- Accepted Time:
- 2011-07-05 16:20:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874663 | Alkermes Inc | ALKS | Pharmaceutical Preparations (2834) | 232472830 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1235595 | L Kathryn Biberstein | 852 Winter St. Waltham MA 02451 | Svp, General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-07-01 | 100,000 | $7.69 | 134,547 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-07-01 | 100,000 | $19.00 | 34,547 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non Qualified Stock Option (Right to Buy) | Disposition | 2011-07-01 | 100,000 | $0.00 | 0 | $7.69 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2004-02-03 | 2013-02-03 | No | 4 | M | Direct |
Footnotes
- This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The range of sale prices was $19.00 to $19.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The option becomes exercisable in equal annual installments over a four year period, at the rate of 25% per year commencing one year after the grant date.